Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Glembatumumab vedotin
Synonyms
Therapy Description

Glembatumumab vedotin (CDX-011) is a conjugate of human anti-glycoprotein NMB (GPNMB) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces cell death in Gpnmb-overexpressing tumor cells (PMID: 25847941, PMID: 31586757).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Glembatumumab vedotin CDX-011 Glembatumumab vedotin (CDX-011) is a conjugate of human anti-glycoprotein NMB (GPNMB) antibody and the cytotoxic agent monomethyl auristatin E (MMAE), which induces cell death in Gpnmb-overexpressing tumor cells (PMID: 25847941, PMID: 31586757).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02302339 Phase II Glembatumumab vedotin A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma Terminated USA 0
NCT02363283 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma Completed USA 0
NCT02487979 Phase II Glembatumumab vedotin Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Completed USA | CAN 1
NCT01997333 Phase II Glembatumumab vedotin Capecitabine Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 0
NCT02713828 Phase Ib/II Glembatumumab vedotin Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung Terminated USA 0


Additional content available in CKB BOOST